268 related articles for article (PubMed ID: 30913868)
21. Metabolic tumor volume derived from
Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
23. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
[TBL] [Abstract][Full Text] [Related]
25. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of interim
Sun N; Qiao W; Xing Y; Wang T; Zhao J
Ann Hematol; 2023 Apr; 102(4):795-800. PubMed ID: 36806973
[TBL] [Abstract][Full Text] [Related]
27. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
[TBL] [Abstract][Full Text] [Related]
28.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
29. Prognostic value of
Geng H; Lian K; Zhang W
Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
[TBL] [Abstract][Full Text] [Related]
31. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer.
Shim SH; Kim DY; Lee DY; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
BJOG; 2014 Aug; 121(9):1097-106; discussion 1106. PubMed ID: 24397772
[TBL] [Abstract][Full Text] [Related]
32. Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.
Kitadate A; Narita K; Fukumoto K; Terao T; Tsushima T; Kobayashi H; Abe Y; Miura D; Takeuchi M; Machida Y; Matsue K
Cancer Med; 2020 Aug; 9(15):5509-5518. PubMed ID: 32558387
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
35. The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK + NSCLC.
Agüloğlu N; Aksu A; Unat DS; Akyol M
Nucl Med Commun; 2022 Dec; 43(12):1217-1224. PubMed ID: 36345766
[TBL] [Abstract][Full Text] [Related]
36. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
38. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma.
Albano D; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Apr; 33(4):280-287. PubMed ID: 30788775
[TBL] [Abstract][Full Text] [Related]
40. Prognostic values of baseline, interim and end-of therapy
Zhou Y; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
Cancer Manag Res; 2019; 11():6871-6885. PubMed ID: 31413633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]